Prevalence and incidence of tuberculosis infection among healthcare workers in chest diseases hospitals, Bangladesh: Putting infection control into context.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
05
2022
accepted:
30
08
2023
medline:
27
9
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
epublish
Résumé
Healthcare workers (HCWs) are at increased risk of tuberculosis infection (TBI). We estimated the prevalence and incidence of TBI and risk factors among HCWs in Bangladeshi hospitals to target TB infection prevention and control (IPC) interventions. During 2013-2016, we conducted a longitudinal study among HCWs in four chest disease hospitals. At baseline, we administered a questionnaire on sociodemographic and occupational factors for TB, tuberculin skin tests (TST) in all hospitals, and QuantiFERON ®-TB Gold in-Tube (QFT-GIT) tests in one hospital. We assessed factors associated with baseline TST positivity (induration ≥10mm), TST conversion (induration increase ≥10mm from baseline), baseline QFT-GIT positivity (interferon-gamma ≥0.35 IU/mL), and QFT-GIT conversion (interferon-gamma <0.35 IU/mL to ≥0.35 IU/mL). We included factors with a biologically plausible relationship with TBI identified in prior studies or having an association (p = <0.20) in the bivariate analyses with TST positivity or QFT-GIT positivity in multivariable generalized linear models. The Kaplan-Meier was used to estimate the cumulative TBI incidence rate per 100 person-years. Of the 758 HCWs invited, 732 (97%) consented to participate and 731 completed the one-step TST, 40% had a positive TST result, and 48% had a positive QFT-GIT result. In multivariable models, HCWs years of service 11-20 years had 2.1 (95% CI: 1.5-3.0) times higher odds of being TST-positive and 1.6 (95% CI 1.1-2.5) times higher odds of QFT-GIT-positivity at baseline compared with those working ≤10 years. HCWs working 11-20 years in pulmonary TB ward had 2.0 (95% CI: 1.4-2.9) times higher odds of TST positivity, and those >20 years had 2.5 (95% CI: 1.3-4.9) times higher odds of QFT-GIT-positivity at baseline compared with those working <10 years. TBI incidence was 4.8/100 person-years by TST and 4.2/100 person-years by QFT-GIT. Females had 8.5 (95% CI: 1.5-49.5) times higher odds of TST conversion than males. Prevalent TST and QFT-GIT positivity was associated with an increased number of years working as a healthcare worker and in pulmonary TB wards. The incidence of TBI among HCWs suggests ongoing TB exposure in these facilities and an urgent need for improved TB IPC in chest disease hospitals in Bangladesh.
Sections du résumé
BACKGROUND
BACKGROUND
Healthcare workers (HCWs) are at increased risk of tuberculosis infection (TBI). We estimated the prevalence and incidence of TBI and risk factors among HCWs in Bangladeshi hospitals to target TB infection prevention and control (IPC) interventions.
METHODS
METHODS
During 2013-2016, we conducted a longitudinal study among HCWs in four chest disease hospitals. At baseline, we administered a questionnaire on sociodemographic and occupational factors for TB, tuberculin skin tests (TST) in all hospitals, and QuantiFERON ®-TB Gold in-Tube (QFT-GIT) tests in one hospital. We assessed factors associated with baseline TST positivity (induration ≥10mm), TST conversion (induration increase ≥10mm from baseline), baseline QFT-GIT positivity (interferon-gamma ≥0.35 IU/mL), and QFT-GIT conversion (interferon-gamma <0.35 IU/mL to ≥0.35 IU/mL). We included factors with a biologically plausible relationship with TBI identified in prior studies or having an association (p = <0.20) in the bivariate analyses with TST positivity or QFT-GIT positivity in multivariable generalized linear models. The Kaplan-Meier was used to estimate the cumulative TBI incidence rate per 100 person-years.
RESULTS
RESULTS
Of the 758 HCWs invited, 732 (97%) consented to participate and 731 completed the one-step TST, 40% had a positive TST result, and 48% had a positive QFT-GIT result. In multivariable models, HCWs years of service 11-20 years had 2.1 (95% CI: 1.5-3.0) times higher odds of being TST-positive and 1.6 (95% CI 1.1-2.5) times higher odds of QFT-GIT-positivity at baseline compared with those working ≤10 years. HCWs working 11-20 years in pulmonary TB ward had 2.0 (95% CI: 1.4-2.9) times higher odds of TST positivity, and those >20 years had 2.5 (95% CI: 1.3-4.9) times higher odds of QFT-GIT-positivity at baseline compared with those working <10 years. TBI incidence was 4.8/100 person-years by TST and 4.2/100 person-years by QFT-GIT. Females had 8.5 (95% CI: 1.5-49.5) times higher odds of TST conversion than males.
CONCLUSIONS
CONCLUSIONS
Prevalent TST and QFT-GIT positivity was associated with an increased number of years working as a healthcare worker and in pulmonary TB wards. The incidence of TBI among HCWs suggests ongoing TB exposure in these facilities and an urgent need for improved TB IPC in chest disease hospitals in Bangladesh.
Identifiants
pubmed: 37756289
doi: 10.1371/journal.pone.0291484
pii: PONE-D-22-14779
pmc: PMC10529546
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0291484Subventions
Organisme : ACL HHS
ID : U01GH001207
Pays : United States
Informations de copyright
Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2020 Dec 17;15(12):e0243951
pubmed: 33332458
New Microbiol. 2009 Oct;32(4):369-76
pubmed: 20128443
PLoS One. 2021 Feb 16;16(2):e0246923
pubmed: 33592049
Ann Intern Med. 1994 Jan 1;120(1):71-9
pubmed: 8250459
Evid Based Spine Care J. 2012 Feb;3(1):9-12
pubmed: 23236300
Thorax. 2012 Jan;67(1):62-70
pubmed: 21228420
PLoS One. 2019 Jul 8;14(7):e0219131
pubmed: 31283794
Health Policy Plan. 2013 Jan;28(1):100-9
pubmed: 22427258
Am J Infect Control. 2014 Mar;42(3):305-10
pubmed: 24406254
Cad Saude Publica. 2017 Dec 18;33(12):e00154916
pubmed: 29267691
BMC Infect Dis. 2016 Nov 4;16(1):633
pubmed: 27814757
Infect Control Hosp Epidemiol. 2001 Feb;22(2):88-93
pubmed: 11232884
Lancet Infect Dis. 2015 Mar;15(3):310-9
pubmed: 25681063
Biochem Med (Zagreb). 2012;22(3):276-82
pubmed: 23092060
Infect Control Hosp Epidemiol. 2009 Mar;30(3):215-21
pubmed: 19191484
Int J Tuberc Lung Dis. 2007 Jun;11(6):593-605
pubmed: 17519089
Eur Respir J. 2019 Apr 18;53(4):
pubmed: 30792341
PLoS One. 2014 Feb 19;9(2):e89085
pubmed: 24586516
Annu Rev Immunol. 2013;31:475-527
pubmed: 23516984
MMWR Recomm Rep. 2000 Jun 9;49(RR-6):1-51
pubmed: 10881762
N Engl J Med. 2015 May 28;372(22):2127-35
pubmed: 26017823
JAMA. 2005 Jun 8;293(22):2746-55
pubmed: 15941804
PLoS One. 2016 Oct 6;11(10):e0164034
pubmed: 27711155
Paediatr Perinat Epidemiol. 2018 Jul;32(4):390-397
pubmed: 29782045
Tuberc Res Treat. 2014;2014:182836
pubmed: 25243086
Lancet Infect Dis. 2004 Dec;4(12):761-76
pubmed: 15567126
MMWR Recomm Rep. 2010 Jun 25;59(RR-5):1-25
pubmed: 20577159
Int J Infect Dis. 2019 Feb;79:26-33
pubmed: 30471404
PLoS One. 2015 Jun 12;10(6):e0129792
pubmed: 26070207
Chest. 2008 May;133(5):1196-202
pubmed: 18263689
Int J Tuberc Lung Dis. 2005 Jun;9(6):686-8
pubmed: 15971398
Am J Respir Crit Care Med. 2014 Jan 1;189(1):77-87
pubmed: 24299555
BMC Infect Dis. 2015 Mar 29;15:165
pubmed: 25879423
PLoS Med. 2006 Dec;3(12):e494
pubmed: 17194191
Clin Vaccine Immunol. 2017 May 5;24(5):
pubmed: 28249842
Eur Respir J. 2016 Jul;48(1):168-78
pubmed: 27230438
Am J Respir Crit Care Med. 1999 Jan;159(1):15-21
pubmed: 9872812
Am J Epidemiol. 2013 Feb 15;177(4):292-8
pubmed: 23371353
Clin Infect Dis. 2020 Oct 23;71(7):1627-1634
pubmed: 32044987
Indian Dermatol Online J. 2012 Jan;3(1):2-6
pubmed: 23130251
PLoS One. 2012;7(7):e40545
pubmed: 22808189
BMC Public Health. 2014 Aug 30;14:891
pubmed: 25174848
Lancet Infect Dis. 2005 Oct;5(10):629-36
pubmed: 16183517
PLoS One. 2014 Apr 04;9(4):e93986
pubmed: 24705675
J Bras Pneumol. 2011 Sep-Oct;37(5):636-45
pubmed: 22042396
PLoS One. 2009 Aug 27;4(8):e6798
pubmed: 19710920
Int J Tuberc Lung Dis. 2011 Jan;15 Suppl 1:S1-25
pubmed: 21276325
Eur Respir J. 2019 Sep 12;54(3):
pubmed: 31221810